DR. STEVEN BRIAN LANDAU, MD
Osteopathic Medicine at Tanglewood Rd, Wellesley, MA

2004024, Dec 9, 2004

Jun 3, 2004

10/859922

Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Matthew Fraser - Apex NC, US

DYNOGEN PHARMACEUTICALS, INC. - BOSTON MA

A61K031/195, A61K031/137

514/561000, 514/650000

The invention relates to a method of treating at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis comprising coadministering to said subject a first amount of an subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative, wherein the first and second amounts together comprise a therapeutically effective amount. The coadministration of a first amount of an subunit calcium channel ligand and a second amount of a substituted aminomethyl-phenyl-cyclohexane derivative can result in an enhanced or synergistic therapeutic effect, wherein the combined effect is greater than the additive effect resulting from separate administration of the first amount of the subunit calcium channel ligand and the second amount of the substituted aminomethyl-phenyl-cyclohexane derivative.

2006024, Nov 2, 2006

Apr 7, 2006

11/400666

Matthew Fraser - Apex NC, US
Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Daniel Ricca - Rougemont NC, US

Dynogen Pharmaceuticals, Inc. - Waltham MA

A61K 31/22, A61K 31/195, A61K 31/16

514551000, 514561000, 514626000

A method is provided for using αδ subunit calcium channel modulators or other compounds that interact with the αδ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, αδ subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

2009004, Feb 19, 2009

Oct 20, 2008

12/288390

Steven B. Landau - Wellesley MA, US
Theodore T. Ashburn - Boston MA, US

A61K 31/44, A61P 1/04

514301

The present invention relates to method of treating a gastrointestinal motility disorder in a subject in need of treatment comprising coadministering to said subject a first amount of a compound having 5-HTreceptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof; and a second amount of at least one gastric acid suppressing agent (e.g., a proton pump inhibitor, an Hreceptor antagonist or a pharmaceutically acceptable salt, hydrate or solvate thereof; or an acid pump antagonist or pharmaceutically acceptable salt, hydrate or solvate thereof) wherein the first and second amounts together comprise a therapeutically effective amount. In particular, the method is for treating GERD, including nocturnal GERD. The invention further relates to a method of treating nocturnal GERD comprising administering to a subject in need thereof a therapeutically effective amount of a compound having 5-HTreceptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The invention further relates to a method of increasing esophageal motility in a subject in need thereof. The method of increasing esophageal motility can be achieved by administration of a compound having 5-HTreceptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The coadministration can also be used to increase esophageal motility.

2005005, Mar 17, 2005

Aug 27, 2004

10/928624

Steven Landau - Wellesley MA, US
Theodore Ashburn - Boston MA, US

Dynogen Pharmaceuticals, Inc. - Waltham MA

A61K031/4439

514338000

The present invention relates to method of treating a gastrointestinal motility disorder in a subject in need of treatment comprising coadministering to said subject a first amount of a compound having 5-HTreceptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof; and a second amount of at least one gastric acid suppressing agent (e.g., a proton pump inhibitor, an Hreceptor antagonist or a pharmaceutically acceptable salt, hydrate or solvate thereof; or an acid pump antagonist or pharmaceutically acceptable salt, hydrate or solvate thereof) wherein the first and second amounts together comprise a therapeutically effective amount. In particular, the method is for treating GERD, including nocturnal GERD. The invention further relates to a method of treating nocturnal GERD comprising administering to a subject in need thereof a therapeutically effective amount of a compound having 5-HTreceptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The invention further relates to a method of increasing esophageal motility in a subject in need thereof. The method of increasing esophageal motility can be achieved by administration of a compound having 5-HTreceptor agonist activity or a pharmaceutically acceptable salt, hydrate or solvate thereof. The coadministration can also be used to increase esophageal motility.

2005003, Feb 10, 2005

Jun 11, 2004

10/866593

Steven Landau - Wellesley MA, US

A61K031/551, A61K031/519

514218000, 514252160, 514260100

The invention relates to a method of treating functional bowel disorders in a subject in need of treatment. The method comprises administering to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HTreceptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity. The invention further relates to a method of treating a functional bowel disorder in a subject in need thereof, comprising coadministering to said subject a first amount of a 5-HTantagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount. In addition, the method of the invention comprises administering a NARI alone. The functional bowel disorders which can be treated according to the method of the invention include IBS, functional abdominal bloating, functional constipation and functional diarrhea.

2006026, Nov 23, 2006

Mar 22, 2004

10/549829

Matthew Fraser - Apex NC, US
Karl Thor - Morrisville NC, US
Edward Burgard - Chapel Hill NC, US
Lee Brettman - Sudbury MA, US
Steven Landau - Wellesley MA, US
Daniel Ricca - Rougemont NC, US

A61K 31/195, A61K 31/165

514561000, 514621000

A method is provided for using αδ subunit calcium channel modulators or other compounds that interact with the αδ calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat pain. According to the present invention, αδ subunit calcium channel modulators include GABA analogs (e.g., gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, β3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.

2004021, Oct 28, 2004

Jan 30, 2004

10/769071

Edward Burgard - Chapel Hill NC, US
Steven Landau - Wellesley MA, US
Matthew Fraser - Apex NC, US

Dynogen Pharmaceuticals, Inc. - Boston MA

A61K009/20

424/464000

The invention relates to methods of using sodium channel modulators, particularly TTX-R sodium channel modulators and/or activity dependent sodium channel modulators to treat gastrointestinal tract disorders, particularly inflammatory bowel disorders and irritable bowel syndrome.

2008026, Oct 30, 2008

Feb 8, 2008

12/069439

Steven B. Landau - Wellesley MA, US
Suhail Nurbhai - Sudbury MA, US

Dynogen Pharmaceuticals, Inc. - Waltham MA

A61K 31/439, A61P 1/00

514294

The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof.

7094786, Aug 22, 2006

May 14, 2004

10/846979

Steven B. Landau - Wellesley MA, US
Cheryl L. Miller - Natick MA, US
Karl B. Thor - Morrisville NC, US

Dynogen Pharmaceuticals, Inc. - Waltham MA

A61K 31/496

51425216

Methods are disclosed for the treatment of nausea and vomiting in a patient suffering therefrom comprising administering 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine.